Margetuximab Approved for HER2+ Metastatic Breast Cancer ...Middle East

Medscape - News
A new monoclonal antibody targeting HER2 in breast cancer, margetuximab-cmkb, has shown superiority over trastuzumab in improving progression-free survival in heavily pretreated women. FDA Approvals

Read More Details
Finally We wish PressBee provided you with enough information of ( Margetuximab Approved for HER2+ Metastatic Breast Cancer )

Apple Storegoogle play

Also on site :